title: [Mast cell activation syndrome].
abstract: BACKGROUND
  The description of a monoclonal mast cell activation syndrome in patients with anaphylaxis, who fulfill one or two minor-criteria of mastocytosis, has led to a search for new unrecognized mast cell activation syndromes.
  
  
  OBJECTIVE
  New classification of mast cell diseases including well-known diseases is provided in order to be able to better recognize and describe new entities.
  
  
  METHODS
  The term mast cell activation has been defined by verifiable scientific objective and subjective criteria, and known and idiopathic mast cell activation syndromes have been classified.
  
  
  RESULTS
  Mast cell activation cannot be defined by symptoms alone, as different diseases and conditions, including those with contribution of different cell types and somatization disorders may lead to similar symptoms. For this reason the preclinical checkpoint mast cell activation was defined to require typical symptoms in combination with demonstration of mast cell mediator release in (an acute) episode(s) as well as with a good response to mast cell mediator-directed therapy. Mast cell activation syndromes were classified in primary (e.g. mastocytosis), secondary (e.g. IgE-mediated allergy) and idiopathic forms.
  
  
  CONCLUSIONS
  Only through a deeper understanding of mast cell diseases, can new previously unrecognized idiopathic mast cell activation syndrome entities  be described and analyzed.
authors: Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Klinikums rechts der Isar der Technischen Universität München. knut.brockow@lrz.tu-muenchen.de
authors: K
authors: K
authors: Brockow
mesh_terms: D000707:Anaphylaxis / Q000188:drug therapy / Q000276:immunology*; D003937:Diagnosis, Differential; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D008407:Mast Cells / Q000187:drug effects / Q000276:immunology*; D008415:Mastocytosis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D013577:Syndrome; D053802:Tryptases / Q000097:blood
chemical_list: D006633:Histamine Antagonists; D053802:Tryptases
references: J Allergy Clin Immunol. 2011 Jul;128(1):147-152.e2
references: 21621255
references: Blood. 2007 Oct 1;110(7):2331-3
references: 17638853
references: J Allergy Clin Immunol. 2010 Dec;126(6):1099-104.e4
references: 21035176
references: Curr Allergy Asthma Rep. 2011 Aug;11(4):292-9
references: 21523372
references: Immunol Allergy Clin North Am. 2006 Aug;26(3):451-63
references: 16931288
references: J Allergy Clin Immunol. 2004 Jul;114(1):3-11; quiz 12
references: 15241337
references: Allergy. 2008 Feb;63(2):226-32
references: 18186813
references: Int Arch Allergy Immunol. 2007;142(2):158-64
references: 17057414
references: Int Arch Allergy Immunol. 2012;157(3):215-25
references: 22041891
references: Chem Immunol Allergy. 2010;95:110-124
references: 20519885
references: Int Arch Allergy Immunol. 2012;159(1):1-5
references: 22555026
references: Int Arch Allergy Immunol. 2002 Feb;127(2):133-6
references: 11919423
references: Eur J Clin Invest. 2007 Jun;37(6):435-53
references: 17537151
references: Blood. 2008 Aug 15;112(4):946-56
references: 18684881
references: Physiol Rev. 1997 Oct;77(4):1033-79
references: 9354811